Scott Tarriff - Nov 1, 2023 Form 4 Insider Report for EAGLE PHARMACEUTICALS, INC. (EGRX)

Signature
/s/ Scott Tarriff
Stock symbol
EGRX
Transactions as of
Nov 1, 2023
Transactions value $
-$299,309
Form type
4
Date filed
11/3/2023, 04:39 PM
Previous filing
Oct 4, 2023
Next filing
Jan 9, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EGRX Common Stock Sale -$151K -10.9K -1.93% $13.82 556K Nov 1, 2023 Direct F1, F2
transaction EGRX Common Stock Sale -$148K -10.7K -1.92% $13.87 545K Nov 2, 2023 Direct F1, F3
holding EGRX Common Stock 993K Nov 1, 2023 By Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 15, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.64 to $14.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $14.20 inclusive.
F4 The shares are held by the Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 (the "Trust") for the benefit of the Reporting Person's spouse and children. The Reporting Person does not have investment control over the shares held by the Trust and disclaims beneficial ownership of the shares, except to any pecuniary interest therein, if any.